NCT06514651RecruitingPhase 1
Study to evaluate the safety of MAQ-001 as monotherapy and combination therapy in patients with advanced cancers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Mar 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 30 Oct 2023
- Start date
- 29 May 2024
- Lead sponsor
- MabQuest Therapeutics S.A.
- Diseases
- Kidney cancer, Melanoma, Lung cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer
- NCT number
- NCT06514651
- EU CT number
- 2023-507774-41-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
| Centre De Lutte Contre Le Cancer Eugene Marquis Coordinator of this site? Confirm its status | Rennes Cedex | France | Recruiting |
| Institut Universitaire Du Cancer Toulouse-Oncopole Coordinator of this site? Confirm its status | Toulouse Cedex 9 | France | Recruiting |
| Institut Gustave Roussy Coordinator of this site? Confirm its status | Villejuif Cedex | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.